Ready for iCRO business recovery in 2024 with all-times high order backlog
The 7% drop in FY 2023 sales vs. 2022 did not come as a surprise as the first three quarters of 2023 showed a continued hamper of the iCRO business. Nonetheless, Q4 2023 revenues stood at + 4% vs. Q4 2022. Despite the flattish results, we are highly encouraged about iCRO business recovery as the coMedian Technologies is engaged in medical imaging. Co. develops software applications for the interpretation and management of medical images, whose purpose is to automatically detect and quantitatively measure abnormalities that may be signs of diseases. In addition to being involved in patient care applications, Co.'s software is used today used by biotechnology companies and pharmaceutical companies during their oncology clinical trials. Co.'s activities are structured around three strategic areas: Imaging for patients with cancer; Imaging for oncology clinical trials and Imaging Phenomics.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.